The total sales of inflammatory bowel disease (IBD) drugs are estimated to reach approximately $10.2 billion in the US in 2023, according to analysts. The increase in IBD biologic treatments has been a major driving force in the growth of this market in recent years. In 2007, AbbVie’s Humira received approval from the FDA to […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!